FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended oral dose of Viekirax is two 12.5 mg / 75 mg / 50 mg tablets once daily with food.
Croatian: Preporučena peroralna doza lijeka Viekirax je dvije tablete od 12,5 mg / 75 mg / 50 mg jedanput na dan s hranom.
English: Darunavir, dosed 800 mg once daily, if administered at the same time as Viekirax and dasabuvir, can be used in the absence of extensive PI resistance (darunavir exposure lowered).
Croatian: Darunavir, u dozi od 800 mg jedanput dnevno, ukoliko se primjenjuje u isto vrijeme s lijekom Viekirax i dasabuvirom, smije se koristiti ako kod bolesnika nema izražene rezistencije na inhibitor proteaze (PI) (smanjena izloženost darunaviru).
English: Patients with moderate to severe hepatic impairment (Child-Pugh B or C) (see section 5.2).
Croatian: Bolesnici s umjerenim do teškim oštećenjem jetre (Child-Pugh B ili C) (vidjeti dio 5.2).
English: Co-administration of Viekirax with or without dasabuvir can decrease exposures of medicinal products that are metabolized by CYP2C19 (e.g. lansoprazole, esomeprazole, s-mephenytoin), which may require dose adjustment/clinical monitoring.
Croatian: Istodobna primjena lijeka Viekirax s dasabuvirom ili bez njega može smanjiti izloženost lijekovima koji se metaboliziraju posredstvom CYP2C19 (npr. lanzoprazol, esomeprazol, s-mefenitoin) što može zahtijevati prilagodbu doze/kliničko praćenje.
English: Drug interactions were evaluated for the Viekirax and dasabuvir regimen, but not for the Viekirax without dasabuvir, with carbamazepine, furosemide, zolpidem, darunavir twice daily, darunavir (evening administration), atazanavir (evening administration), rilpivirine, abacavir/lamivudine, dolutegravir, metformin, sulfamethoxazole/trimethoprim, cyclobenzaprine, carisoprodol, hydrocodone/
Croatian: Interakcije između lijekova ocijenjene su za režim liječenja lijekom Viekirax i dasabuvirom, ali ne i za režim liječenja lijekom Viekirax bez dasabuvira, s karbamazepinom, furosemidom, zolpidemom, darunavirom dvaput na dan, darunavirom (primjena navečer), atazanavirom (primjena navečer), rilpivirinom, abakavirom/lamivudinom, dolutegravirom, metforminom, sulfametoksazolom/trimetoprimom, ciklobenzaprinom, karisoprodolom, hidrokodonom/paracetamolom ili diazepamom.
English: Use with colchicine
Croatian: Primjena s kolhicinom
English: Coadministration with enzyme inducers may increase the risk of adverse reactions and ALT elevations (see Table 2).
Croatian: Istodobna primjena s induktorima enzima može povećati rizik od nuspojava i porasta razine ALT-a (vidjeti Tablicu 2).
English: Clinical monitoring and dose adjustment may be required for levothyroxine
Croatian: Može biti potrebno kliničko praćenje i prilagodba doze levotiroksina.
English: In HCV-infected subjects, in comparison to those without cirrhosis, paritaprevir AUC increased to 2.2- to 2.4-fold for those with compensated cirrhosis (Child-Pugh A) and 3- to 4-fold for those with Child-Pugh B cirrhosis.
Croatian: U ispitanika inficiranih HCV-om, u usporedbi s ispitanicima bez ciroze, vrijednost AUC-a paritaprevira povećala se 2,2 do 2,4 puta u ispitanika s kompenziranom cirozom (Child-Pugh stadij A) i 3 do 4 puta u ispitanika s cirozom Child-Pugh stadija B.
English: Food increased the exposure (AUC) of ombitasvir, paritaprevir and ritonavir by up to 82%, 211% and 49%, respectively relative to the fasting state.
Croatian: U odnosu na primjenu natašte, hrana je povećala izloženost (AUC) ombitasviru do 82%, paritapreviru do 211% i ritonaviru do 49%.
English: Potential for other medicinal products to affect the pharmacokinetics of ombitasvir, paritaprevir, and dasabuvir
Croatian: Mogući utjecaj drugih lijekova na farmakokinetiku ombitasvira, paritaprevira i dasabuvira
English: Table 17 shows the primary efficacy analysis of SVR12 performed on subjects with HCV GT1/HIV-1 coinfection that received recommended regimen in Part 2 of the TURQUOISE-I study.
Croatian: Tablici 17 prikazani su rezultati primarne analize djelotvornosti prema podacima za SVR12 u ispitanika s istodobnom infekcijom HCV-om genotipa 1 i HIV-om tipa 1 koji su primali preporučeni režim liječenja u 2. dijelu ispitivanja TURQUOISE-I.
English: 300 mg once daily (given at the same time)
Croatian: 300 mg jedanput na dan (primijenjen u isto vrijeme)
English: Ombitasvir was approximately 99.9% bound to human plasma proteins.
Croatian: Približno 99,9% ombitasvira vezalo se za proteine u ljudskoj plazmi.
English: Paritaprevir was positive in an in vitro human chromosome aberration test. Paritaprevir was negative in a bacterial mutation assay, and in two in vivo genetic toxicology assays (rat bone marrow micronucleus and rat liver Comet tests).
Croatian: Paritaprevir je bio negativan u testu mutagenosti na bakterijama i u dva genetska toksikološka testa in vivo (mikronukleusni test na koštanoj srži štakora i Cometov test na jetri štakora).
English: Rilpivirine was also administered in the evening with food and at night 4 hours after dinner with Viekirax + dasabuvir in other two arms in the study.
Croatian: Rilpivirin je u druge dvije skupine u ispitivanju također primijenjen navečer s hranom te u noći 4 sata nakon obroka s lijekom Viekirax + dasabuvir.
English: No dose adjustment of gemfibrozil is necessary.
Croatian: Nije potrebno prilagođavati dozu gemfibrozila.
English: HIV ANTIVIRALS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Rilpivirine2
Croatian: ANTIVIROTICI ZA LIJEČENJE HIV-a: NENUKLEOZIDNI INHIBITORI REVERZNE TRANSKRIPTAZE rilpivirin2
English: Ethinyloestradiol is contraindicated in combination with Viekirax (see sections 4.3 and 4.4).
Croatian: Etinilestradiol je kontraindiciran u kombinaciji s lijekom Viekirax (vidjeti dijelove 4.3 i 4.4).
English: CORAL-I: treatment-naïve or pegIFN + RBV-experienced, at least 3 months post liver transplant or 12 months post renal transplant
Croatian: CORAL-I: ispitanici prethodno neliječeni ili prethodno liječeni pegIFN i RBV kod kojih je prošlo barem 3 mjeseca od transplantacije jetre ili 12 mjeseci od transplantacije bubrega Dizajn:
English: Medicinal products renally excreted via transport proteins Ombitasvir, paritaprevir, and ritonavir do not inhibit organic anion transporter (OAT1) in vivo as shown by the lack of interaction with tenofovir (OAT1 substrate).
Croatian: Lijekovi koji se izlučuju putem bubrega posredstvom prijenosnih proteina Ombitasvir, paritaprevir i ritonavir ne inhibiraju prijenosnik organskih aniona (OAT1) in vivo što je dokazano nepostojanjem interakcije s tenofovirom (supstrat prijenosnika OAT1).
English: Tell your doctor or pharmacist before taking Viekirax also if you are using hormonal contraceptives.
Croatian: Isto tako, obratite se svome liječniku ili ljekarniku prije nego uzmete lijek Viekirax ako koristite hormonsku kontracepciju.
English: The overall safety profile in HCV-infected transplant recipients who were administered Viekirax and dasabuvir and ribavirin (in addition to their immunosuppressant medications) was similar to subjects treated with Viekirax and dasabuvir and ribavirin in phase 3 clinical trials, although some adverse reactions were increased in frequency.
Croatian: Ukupan sigurnosni profil u ispitanika s transplantiranom jetrom s infekcijom HCV-om koji su liječeni lijekom Viekirax, dasabuvirom i ribavirinom (uz imunosupresivne lijekove) bio je sličan onome u ispitanika liječenih lijekom Viekirax, dasabuvirom i ribavirinom u kliničkim ispitivanjima faze III iako su neke nuspojave imale veću učestalost.
English: Viekirax contains the active substances ombitasvir, paritaprevir and ritonavir.
Croatian: Viekirax sadrži djelatne tvari ombitasvir, paritaprevir i ritonavir.
English: No human data on the effect of Viekirax on fertility are available.
Croatian: Plodnost Nema dostupnih podataka o utjecaju lijeka Viekirax na plodnost u ljudi.
English: CYP2C19 substrates evaluated in drug interaction studies include omeprazole and escitalopram (see Table 2).
Croatian: Supstrati za CYP2C19 ispitani u ispitivanjima interakcija lijekova uključuju omeprazol i escitalopram (vidjeti Tablicu 2).
English: OATP1B1/3 substrates evaluated in drug interaction studies include pravastatin and rosuvastatin (see Table 2).
Croatian: OATP1B1/3 supstrati ocijenjeni u ispitivanjima interakcija uključuju pravastatin i rosuvastatin (vidjeti Tablicu 2).
English: Tell your doctor or pharmacist before taking Viekirax, if you are taking any of the medicines in the table below.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Viekirax ako uzimate bilo koji od lijekova navedenih u sljedećoj tablici.
English: CYP3A4 inhibitors:
Croatian: CYP3A4 inhibitori:
English: Ritonavir is not active against HCV. Ritonavir is a CYP3A inhibitor that increases the systemic exposure of the CYP3A substrate paritaprevir.
Croatian: Ritonavir je inhibitor CYP3A koji povećava sistemsku izloženost CYP3A substratu paritapreviru.
English: Examples of contraindicated strong CYP3A4 inhibitors are provided below.
Croatian: Primjeri kontraindiciranih snažnih CYP3A4 inhibitora dani su u nastavku.
English: BCRP substrates evaluated in drug interaction studies include rosuvastatin (see Table 2).
Croatian: Supstrati prijenosnika BCRP u ispitivanjima interakcija lijekova uključuju rosuvastatin (vidjeti Tablicu 2).
English: Sulfamethoxazole, Trimethoprim
Croatian: sulfametoks azol, trimetoprim
English: Expected in CYP2C19 Extensive Metabolisers:
Croatian: Očekuje se u CYP2C19 ekstenzivnih metabolizatora:
English: Double variants including combinations of V36LM, F43L, Y56H, Q80K or E357K with R155K or with a D168 substitution reduced the activity of paritaprevir by an additional 2 to 3-fold relative to the single R155K or D168 substitution.
Croatian: V36LM, F43L, Y56H, Q80K ili E357K sa R155K ili nekom D168 supstitucije smanjile su aktivnost paritaprevira za dodatna 2 do 3 puta u odnosu na pojedinačnu supstituciju R155K ili D168.
English: ↑ voriconazole ↑ dasabuvir ↑ paritaprevir
Croatian: ↑ vorikonazol ↑ dasabuvir ↑ paritaprevir
English: Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events are contraindicated (see section 4.3 and Table 2).
Croatian: Lijekovi čiji klirens uvelike ovisi o CYP3A i čije su povišene razine u plazmi povezane s ozbiljnim događajima su kontraindicirani (vidjeti dio 4.3 i Tablicu 2).
English: • lomitapide
Croatian: • lomitapid
English: CYP2D6 substrates (e.g. desipramine, metoprolol and dextromethorphan) are not expected to require dose adjustments.
Croatian: Za supstrate za CYP2D6 (npr. dezipramin, metoprolol i dekstrometorfan) zahtijevati prilagodbu doze.
English: Viekirax without dasabuvir may increase the plasma concentrations of dabigatran etexilate.
Croatian: Viekirax bez dasabuvira može povećati koncentracije dabigatraneteksilata u plazmi.
English: Concomitant use of Viekirax and glucocorticoids, particularly long-term use, should only be initiated if the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.5).
Croatian: Istodobna primjena lijeka Viekirax i glukokortikoida, a osobito dugotrajna primjena, smije započeti samo ako moguća korist od liječenja nadmašuje rizik od sistemskih učinaka kortikosteroida (vidjeti dio 4.5).
English: Serious and/or life threatening events have been observed with co-administration of Viekirax and dasabuvir with systemic tacrolimus, and a similar risk can be expected with sirolimus and everolimus.
Croatian: Kod istodobne primjene lijeka Viekirax i dasabuvira sa sistemskim takrolimusom primijećeni su ozbiljni i/ili po život opasni događaji, a sličan se rizik može očekivati i kod primjene sa sirolimusom i everolimusom.
English: Pooled analyses of clinical trials
Croatian: Analiza objedinjenih podataka iz kliničkih ispitivanja
English: Beginning the day after Viekirax and dasabuvir are initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus blood concentrations.
Croatian: Viekirax i dasabuvira, ponovno uvedite takrolimus u sniženoj dozi na temelju koncentracija takrolimusa u krvi.
English: The safety summary is based on pooled data from phase 2 and 3 clinical trials in subjects who received Viekirax and dasabuvir with or without ribavirin.
Croatian: Sažetak sigurnosnog profila temelji se na objedinjenim podacima iz kliničkih ispitivanja faze 2 i 3, u kojima su ispitanici bili liječeni lijekom Viekirax i dasabuvirom s ribavirinom ili bez njega.
English: Substitutions R155C, A156T/V, and D168H/V in HCV NS3 reduced susceptibility to paritaprevir by 40- to 323-fold.
Croatian: Supstitucije R155C, A156T/V i D168H/V u proteinu NS3 HCV-a smanjile su osjetljivost na pariteprevir 40 do 323 puta.
English: Co-administration of Viekirax with or without dasabuvir with medicinal products that are substrates of OATP1B1, OATP1B3, OATP2B1 or OCT1 may increase plasma concentrations of these transporter substrates, potentially requiring dose adjustment/clinical monitoring.
Croatian: Istodobna primjena lijeka Viekirax s dasabuvirom ili bez njega s lijekovima koji su supstrati za OATP1B1, OATP1B3, OATP2B1 ili OCT1 može povisiti koncentraciju supstrata tih prijenosnika u plazmi, što, potencijalno, zahtijeva prilagodbu doze/kliničko praćenje.
English: Talk to your doctor or pharmacist before taking Viekirax if you:
Croatian: Obratite se svom liječniku ili ljekarniku prije nego što uzmete lijek Viekirax ako:
English: Following a 25 mg single dose of 14C-ombitasvir given alone, unchanged parent drug accounted for 8.9% of total radioactivity in human plasma; a total of 13 metabolites were identified in human plasma.
Croatian: Nakon jednokratne doze 14C-ombitasvira od 25 mg primijenjene samostalno, ishodišni spoj u neizmijenjenu obliku činio je 8,9% ukupne radioaktivnosti u plazmi ljudi; ukupno je u plazmi ljudi pronađeno 13 metabolita.
English: 4-24 mg/16 mg once daily8
Croatian: 4-24 mg/1-6 mg jedanput na dan8
English: Contraindicated enzyme inducers are provided in section 4.3 and Table
Croatian: Primjeri kontraindiciranih induktora enzima navode se u dijelu 4.3 i Tablici 2.
English: The activity of paritaprevir was reduced 96-fold by D168V, and 50- to 219-fold by each of the other D168 substitutions.
Croatian: Supstitucija D168V smanjila je aktivnost paritaprevira 96 puta, a svaka druga D168 supstitucija 50 do 219 puta.
English: ANTICONVULSANTS Carbamazepine
Croatian: ANTIKONVULZIVI karbamazepin
English: GT1b Viekirax and dasabuvir (12 weeks)
Croatian: GT1b Viekirax i dasabuvir (12 tjedana)
English: Viekirax with or without dasabuvir was also evaluated without ribavirin in 18 GT1a- and GT4-infected patients; no adverse events of anaemia were seen in these subjects.
Croatian: Viekirax u kombinaciji s dasabuvirom ili bez njega ocjenjivao se i bez istodobne primjene ribavirina u 18 bolesnika s infekcijom genotipom 1a i genotipom 4; u tih ispitanika nisu primijećeni štetni događaji anemije.
English: Ombitasvir, paritaprevir and ritonavir should be administered with food.
Croatian: Učinci hrane Ombitasvir, paritaprevir i ritonavir potrebno je primjenjivati s hranom.
English: Elderly No dose adjustment of Viekirax is warranted in elderly patients (see section 5.2).
Croatian: Nije potrebno prilagođavati dozu lijeka Viekirax u starijih bolesnika (vidjeti dio 5.2).
English: See section 4.2 for dosing recommendations in HCV/HIV-1 co-infected patients.
Croatian: Vidjeti dio 4.2 za preporuke o doziranju u bolesnika s istodobnom infekcijom HCV-om i HIV-om tipa 1.
English: Co-administration of Viekirax and dasabuvir with medicinal products that are moderate or strong enzyme inducers is expected to decrease ombitasvir, paritaprevir, ritonavir and dasabuvir plasma concentrations and reduce their therapeutic effect.
Croatian: Očekuje se da će istodobna primjena lijeka Viekirax i dasabuvira s lijekovima koji su umjereni ili snažni induktori enzima smanjiti plazmatske koncentracije ombitasvira, paritaprevira, ritonavira i dasabuvira te smanjiti njihov terapijski učinak.
English: Medicinal products that inhibit CYP3A4
Croatian: Lijekovi koji inhibiraju CYP3A4
English: HCV GT1- or 4-infected subjects with HIV-1 coinfection were on a stable HIV-1 antiretroviral therapy (ART) regimen that included ritonavir-boosted atazanavir, raltegravir, dolutegravir (Part 2 only), or darunavir (Part 1b and Part 2 GT4 only)-, co-administered with a backbone of tenofovir plus emtricitabine or lamivudine.
Croatian: Ispitanici s istodobnom infekcijom HCV-om genotipa 1 ili 4 i HIV-om tipa 1 bili su na ustaljenoj antiretrovirusnoj terapiji (engl. antiretroviral therapy, ART) za infekciju HIV-om tipa 1 koja je uključivala ritonavirom pojačan atazanavir, raltegravir, dolutegravir (samo u 2. dijelu) ili darunavir (u dijelu 1b i 2. dijelu samo kod infekcije genotipom 4) primijenjene istodobno s okosnicom liječenja tenofovirom s emtricitabinom ili lamivudinom.
English: Resistance to paritaprevir and ombitasvir conferred by variants in NS3 and NS5A respectively, selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterised in the appropriate genotype 1a or 1b replicons.
Croatian: NS3 ili NS5A izdvojenima u staničnoj kulturi ili identificiranima u kliničkim ispitivanjima faze 2b i 3, bila je fenotipski okarakterizirana u odgovarajućim replikonima genotipa 1a ili 1b.
English: Although some cases had previous history of depression, psychiatric illness and/or substance abuse, a causal relation with Viekirax with or without dasabuvir treatment cannot be excluded.
Croatian: Iako su u nekim slučajevima depresija, psihijatrijska bolest i/ili zlouporaba droge bile prisutne u bolesnikovoj anamnezi, ne može se isključiti uzročna povezanost s liječenjem lijekom Viekirax, s dasabuvirom ili bez njega.
English: b. Other includes early drug discontinuation not due to virologic failure missing HCV RNA values in the SVR12
Croatian: Ostalo uključuje ranu obustavu liječenja, ali ne zbog virološkog neuspjeha i nedostatak podataka o razinama HCV RNK u razdoblju određivanja SVR12.
English: Following a 200 mg 14C -paritaprevir dose with 100 mg ritonavir, approximately 88% of the radioactivity was recovered in faeces with limited radioactivity (8.8%) in urine.
Croatian: Nakon primjene doze od 200 mg 14C-paritaprevira sa 100 mg ritonavira, približno 88% radioaktivnosti pronađeno je u fecesu, a ograničena količina radioaktivnosti (približno 8,8%) u mokraći.
English: ↑ nifedipine
Croatian: ↑ nifedipin
English: Compared to the subjects with normal renal function, ombitasvir exposures were comparable in subjects with mild, moderate and severe renal impairment.
Croatian: U usporedbi s ispitanicima koji imaju urednu funkciju bubrega, izloženosti ombitasviru bile su usporedive kod ispitanika koji imaju blago, umjereno i teško oštećenje funkcije bubrega.
English: NA A reduction of hydrocodone dose by 50% and/or clinical monitoring should be considered when administered with Viekirax with or without dasabuvir .
Croatian: NP Mora se razmotriti smanjenje doze hidrokodona za 50% i/ili kliničko praćenje kada se primjenjuje s lijekom Viekirax s dasabuvirom ili bez njega.
English: In vitro data indicate that paritaprevir is a substrate for the human hepatic uptake transporters, OATP1B1 and OATP1B3.
Croatian: In vitro podaci pokazuju da je paritaprevir supstrat za humane prijenosnike unosa u jetru, OATP1B1 i OATP1B3.
English: Mechanism: Increase in paritaprevir exposures may be due to inhibition of CYP3A/efflu x transporters by lopinavir and higher dose of ritonavir
Croatian: : Povećanje izloženosti paritaprevir u moglo bi biti posljedica inhibicije CYP3A/ efluksnih prijenosnika koju uzrokuje lopinavir i viša doza ritonavira.
English: To be noted, darunavir should be taken without ritonavir, since ritonavir 100 mg once daily is provided as part of Viekirax.
Croatian: Potrebno je uzeti u obzir da se darunavir mora primjenjivati bez ritonavira jer se doza od 100 mg ritonavira jedanput dnevno unosi kao dio lijeka Viekirax.
English: Viekirax with dasabuvir is expected to increase the exposure to rosuvastatin more than 3-fold.
Croatian: Očekuje se da primjena lijeka Viekirax u kombinaciji s dasabuvirom povećava izloženost rosuvastatinu više nego trostruko.
English: Co-administration of Viekirax with rilpivirine once daily should only be considered in patients without known QTprolongation, and without other QT-prolongation co ombitasvir paritaprevir
Croatian: Istodobna primjena lijeka Viekirax s rilpivirinom jedanput na dan može se razmotriti samo kod bolesnika bez poznatog produljenja QT-intervala i koji istodobno ne uzimaju druge lijekove koji uzrokuju produljenje QT-intervala.
English: Purpose of the medicine alprazolam, diazepam for anxiety, panic attacks and trouble sleeping ciclosporin, everolimus, sirolimus, tacrolimus to suppress the immune system cyclobenzaprine, carisoprodol for muscle spasms colchicine for patients whose kidney and liver function test are normal for treating gout attacks or familial Mediterranean fever digoxin, amlodipine, nifedipine, valsartan, diltiazem, verapamil, candesartan, losartan for heart problems or high blood pressure encorafenib for skin cancer furosemide for the build-up of too much fluid in the body hydrocodone for pain levothyroxine for thyroid problems rilpivirine, darunavir, atazanavir for HIV infection omeprazole, lansoprazole, esomeprazole for stomach ulcers and other stomach problems ibrutinib, imatinib for the treatment of some cancers of the blood fluvastatin, pitavastatin, pravastatin, rosuvastatin to lower blood cholesterol dabigatran to thin the blood fexofenadine for hay fever s-mephenytoin for epilepsy sulfasalazine for inflammatory bowel disease repaglinide for lowering blood sugar erythromycin for bacterial infections steroid or corticosteroid medicines (such as fluticasone)
Croatian: Namjena lijeka alprazolam, diazepam za liječenje tjeskobe, paničnih napadaja i problema sa spavanjem ciklosporin, everolimus, sirolimus, takrolimus za potiskivanje imunosnog sustava ciklobenzaprin, karisoprodol za liječenje mišićnih grčeva kolhicin za bolesnike kod kojih su testovi pokazali normalnu funkciju bubrega i jetre za liječenje napadaja gihta ili obiteljske mediteranske groznice digoksin, amlodipin, nifedipin, valsartan, diltiazem, verapamil, kandesartan, losartan za liječenje srčanih tegoba ili povišenog krvnog tlaka enkorafenib za rak kože furosemid za izlučivanje prekomjerno nakupljene tekućine u tijelu hidrokodon za liječenje boli levotiroksin za tegobe sa štitnjačom rilpivirin, darunavir, atazanavir za liječenje HIV infekcije omeprazol, lanzoprazol, esomeprazol za liječenje želučanog vrijeda i drugih želučanih tegoba ibrutinib, imatinib za liječenje određenih vrsta raka krvi fluvastatin, pitavastatin, pravastatin, rosuvastatin za snižavanje razine kolesterola u krvi dabigatran za razrjeđivanje krvi feksofenadin za liječenje peludne groznice s-mefenitoin za liječenje epilepsije sulfasalazin za liječenje upalnih bolesti crijeva repaglinid za snižavanje razina šećera u krvi eritromicin za liječenje bakterijskih infekcija steroidni ili kortikosteroidni lijekovi (poput flutikazona)
English: To maximise absorption, Viekirax should be taken with food without regard to fat or calorie content.
Croatian: Kako bi se maksimizirala apsorpcija, lijek Viekirax treba uzimati s hranom, neovisno o udjelu masti ili kalorijskoj vrijednosti obroka.
English: Viekirax tablets are usually taken with other anti-viral medicines such as “dasabuvir” and “ribavirin”.
Croatian: Viekirax tablete se obično uzimaju s drugim antivirusnim lijekovima poput „dasabuvira“ i
English: PROTON PUMP INHIBITORS Omeprazole
Croatian: INHIBITORI PROTONSKE PUMPE omeprazol
English: No clinically relevant changes in dasabuvir, paritaprevir and ombitasvir exposures (based on comparison with historical data) were observed during co-administration.
Croatian: Tijekom istodobne primjene nisu primijećene klinički značajne promjene izloženosti dasabuviru, paritapreviru i ombitasviru (na temelju usporedbe s podacima iz prethodnih ispitivanja).
English: Phase 3 global multicentre studies conducted with Viekirax and dasabuvir with or without ribavirin (RBV).
Croatian: Tablica 6. Globalna, multicentrična ispitivanja faze 3 provedena s lijekom Viekirax i dasabuvirom, u kombinaciji s ribavirinom (RBV) ili bez njega.